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        Humoral immune responses triggered by foreign 
antigens require B cell activation. The activated 
B cell undergoes antibody affi   nity maturation, 
which in higher vertebrates includes somatic 
hypermutation (SHM), gene conversion of an-
tigen-binding V regions, and class switching (  1  ); 
all of these processes require activation-induced 
deaminase (AID) (  2  –  5  ). AID initiates these 
events by deaminating deoxycytosine to deoxy-
uracil in DNA (for review see reference [  6  –  8  ]). 
The resulting dU:dG lesion can be recognized 
by several diff   erent DNA repair pathways to 
create the aforementioned antibody diversifi  ca-
tions. This necessity for immune diversifi  cation 
and suffi   ciency for genome instability also high-
lights AID as an important pathogenic regulator. 
In the immune system, hyper- or hypoexpres-
sion of AID can alter autoimmune pathologies 
(  9  –  11  ). Furthermore, SHM, by way of AID, 
may contribute to lymphomagenesis by mutat-
ing (proto-)oncogenes and tumor suppressor 
genes, or by promoting chromosomal transloca-
tions (  12  –  14  ). There is strong evidence that 
AID is required for c-myc translocation, leading 
to tumorgenesis in a murine model for Burkitt  ’  s 
lymphoma (  15, 16  ). Other nonphysiological 
AID targets include BCL6, CD95/Fas, RHO/
TTF, PAX-5, and PIM1 (  12, 17  –  19  ). Outside 
the immune system, there are indications that 
systemic hyperexpression of AID can induce 
non  –  B cell cancers from lung (  20  ), lymphatic 
(  20  ), and liver (  21  ) tissues. 
  AID has also been implicated as a develop-
mental epigenetic reprogramming factor, and 
its expression levels in oocytes is almost equiva-
lent to that in lymph nodes (  22  ), suggesting 
that AID could be regulated by pathways other 
than B cell activation pathways (e.g., E-box 
proteins [  23  ], NF-    B [  24  ], and Pax5 [  25  ]), 
with hormones being plausible candidates. 
  Several clinical and epidemiological studies 
have indicated that females can have stronger 
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  The immunological targets of estrogen at the molecular, humoral, and cellular level have 
been well documented, as has estrogen  ’  s role in establishing a gender bias in autoimmunity 
and cancer. During a healthy immune response, activation-induced deaminase (AID) deami-
nates cytosines at immunoglobulin (Ig) loci, initiating somatic hypermutation (SHM) and 
class switch recombination (CSR). Protein levels of nuclear AID are tightly controlled, as 
unregulated expression can lead to alterations in the immune response. Furthermore, 
hyperactivation of AID outside the immune system leads to oncogenesis. Here, we demon-
strate that the estrogen  –  estrogen receptor complex binds to the AID promoter, enhancing 
AID messenger RNA expression, leading to a direct increase in AID protein production and 
alterations in SHM and CSR at the Ig locus. Enhanced translocations of the c-myc onco-
gene showed that the genotoxicity of estrogen via AID production was not limited to the Ig 
locus. Outside of the immune system (e.g., breast and ovaries), estrogen induced AID ex-
pression by   >  20-fold. The estrogen response was also partially conserved within the DNA 
deaminase family (APOBEC3B, -3F, and -3G), and could be inhibited by tamoxifen, an 
estrogen antagonist. We therefore suggest that estrogen-induced autoimmunity and onco-
genesis may be derived through AID-dependent DNA instability. 
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after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
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mercial–Share Alike 3.0 Unported license, as described at http://creativecommons
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  We focused our subsequent experiments on the verifi  -
cation that the estrogen-induced stimulation on AID was 
analogous to another known estrogen response gene. Be-
cause we could determine that the expression of gene regu-
lated in breast cancer 1 (a known estrogen response gene) 
(  36  ) had a similar stimulation profi  le in B cells (unpublished 
and more rapid immune responses upon antigen encounter 
(  26, 27  ). This gender bias is also refl  ected in the occurrence 
of pathogenic immune responses, as found in asthma and 
other autoimmune diseases (  28  –  31  ). Several nonimmune pa-
thologies are also strongly infl  uenced by the activity of sex 
hormones, most notably certain types of cancer. Estrogen and 
its biological and synthetic derivatives are thought to be 
  oncogenic for breast and ovarian tissue (  32, 33  ), most often 
being associated with their growth-promoting and diff  erenti-
ating capacity. 
  To further elucidate how AID can be regulated, both 
within and outside the immune system, and to determine 
which signaling pathways could use DNA deaminases as 
DNA instability factors, we analyzed the eff  ect of estrogen on 
AID  ’  s expression and on downstream pathways such as SHM 
and class switch recombination (CSR). We show that AID 
can be up-regulated by estrogen, whereas tamoxifen (Tam) 
can inhibit this stimulation. This eff  ect was most pronounced, 
but not limited to regulation at the level of transcription. 
Treatment with estrogen increased AID protein expression, 
enhanced CSR, augmented mutation frequency in Ig and 
non-Ig genes, and increased the translocation frequency of 
c-myc. Estrogen-induced AID messenger RNA (mRNA) pro-
duction was independent of other B cell stimulatory path-
ways and could be observed outside immune tissue. We were 
able to identify two potential estrogen response elements 
(EREs) near the AID promoter, and determined enhanced 
ER     binding to the promoter after estrogen treatment in vi-
tro and in vivo. APOBEC3, the evolutionarily related DNA 
deaminases (  34  ), were also responsive to estrogen treatment in 
diff  erent tissues and cell types. Our data indicate that the mu-
tagenic DNA deaminases are potentially an important target 
for hormonal regulation. 
    RESULTS   
  Differential effect of sex hormones on AID mRNA 
  Hormones such as estrogen and progesterone exert their bio-
logical eff  ects through binding to their intracellular receptors 
and, upon entering the nucleus, act as transcription factors (  35  ). 
To determine the eff  ects of hormones on AID expression, we 
stimulated isolated murine splenic B cells with IL-4 and LPS, 
which are known to induce AID (  24  ), while adding physio-
logical amounts of progesterone and estrogen. Progesterone 
addition reduced AID mRNA levels by fi  vefold, as revealed 
by quantitative real-time PCR (qRT-PCR;   Fig. 1 A  ).   This 
and all subsequent qRT-PCR analyses were normalized to 
GAPDH expression, and all enhancements or repressions were 
analyzed as relative changes to DMSO. To observe a stimula-
tory eff  ect of estrogen, cells were only treated for a short time 
period (8 h) rather than the usual 24  –  48 h. This was done to 
avoid a possible maximal induction of LPS/IL-4 caused by 
longer treatment. In contrast to progesterone, physiological 
amounts of estrogen were able to enhance AID expression 
threefold in these cells (  Fig. 1 A  ). This antithetical eff  ect of 
  estrogen and progesterone indicated that AID gene regulation 
is embedded within a systemic sex hormone pathway. 
    Figure 1.         The effects of estrogen and progesterone on AID mRNA 
in murine splenic B-cells.   (A) AID mRNA in response to estrogen and 
progesterone treatment in stimulated B cells. Isolated mouse spleen B cells 
were stimulated with LPS and IL-4 and treated with different physi-
ological concentrations of estrogen for 8 h or progesterone for 24 h. 
Unless indicated, DMSO is set to 1, and treatments are represented as 
relative change to DMSO. (B) AID mRNA in response to estrogen treat-
ment in unstimulated B cells after 8 h treatment with physiological 
concentrations of estrogen. (C) AID mRNA induction upon different treat-
ment. Cells were treated with 1 nM estrogen and/or 50 nM Tam (Tam) for 
up to 8 h. DMSO at 0 h is set to 1. All qRT-PCR data are representative of 
three independent experiments, and error bars indicate standard devia-
tions from the mean. Timelines of cell treatments are indicated next to 
the graphs. NT, not treated. For A and B, absolute values as compared 
with GAPDH mRNA are shown in Fig. S10, available at http://www
.jem.org/cgi/content/full/jem.20080521/DC1.   JEM VOL. 206, January 19, 2009 
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the translational inhibitor cycloheximide (CHX), followed 
by stimulation with estrogen, and observed an increase in 
mRNA production equivalent to treatment without inhibi-
tor (Fig. S1 B). This suggested that the eff  ect of estrogen was 
directly mediated on AID  ’  s mRNA synthesis. Because qRT-
PCR of cDNA is a readout of steady-state mRNA, we also 
tested if the increase by estrogen was caused by transcription 
or mRNA metabolism. Treatment of cells with transcription 
inhibitors (actinomycin D [ACT] and     -amanitin [AMA]) 
abrogated the eff  ect of estrogen, indicating that this alteration 
in AID  ’  s mRNA was not caused by message stability (Fig. S1 B). 
As estrogen can aff  ect pre-mRNA to mRNA processing 
(  38  ), we designed qRT-PCR primers to span the complete 
transcription unit of AID (Fig. S2 A, available at http://www
.jem.org/cgi/content/full/jem.20080521/DC1). When we 
compared the relative change in expression of the various 
pre-mRNA  ’  s exons and introns to that of the mature mRNA, 
we found only a minor eff  ect caused by estrogen treatment 
(the 5    -most PCR unit,   <  100 bp away from the start of AID 
gene, was up-regulated to almost the same extent as the ma-
ture mRNA [Fig. S2 B]). The intron between exon 3 and 4 
(7,538  –  7,689 bp) showed a marginal increase in response to 
estrogen over that of the mature RNA, indicating a potential 
region for estrogen-induced splicing of AID RNA. Because 
data), it seemed likely that the AID gene could also be acti-
vated in uninduced B cells with estrogen. Stimulation of 
isolated splenic B cells with physiological amounts of estro-
gen produced a sevenfold increase in AID mRNA (  Fig. 1 B  ). 
This induction began to plateau at 4 h, with the earliest in-
dication of an increase detectable at     2 h (  Fig. 1 C  ). 
  In most systems, the synthetic hormone Tam acts as an 
antagonist to estrogen stimulation, presumably by binding 
to the estrogen receptor (ER) and altering its DNA bind-
ing capacity (  37  ). The presence of Tam during the estrogen 
treatment of isolated splenic B cells inhibited the stimulatory 
activity, whereas Tam on its own had only a limited eff  ect on 
AID mRNA expression at the concentration used (  Fig. 1 C  , 
Estrogen 1 nM/Tam and Tam, respectively). Interestingly, 
at very low concentrations, Tam can have a stimulatory 
eff  ect on AID mRNA (Fig. S1 A, available at http://www
.jem.org/cgi/content/full/jem.20080521/DC1), which may 
refl  ect Tam  ’  s agonistic activity (see Discussion). 
  Hormonal regulation of AID mRNA is predominantly 
via transcription 
  Although we were able to observe an increase in AID mRNA 
at 2 h (  Fig. 1  ), we needed to determine if this regulation 
was direct or indirect. We pretreated splenic B cells with 
    Figure 2.         Human AID promoter analysis for hormone response elements.   (A) Schematic representation of potential EREs (square) and NF-   B  sites 
(circle) and their respective locations in the human promoter. The indicated promoter regions (marked A  –  E) were inserted into a luciferase reporter con-
struct with a minimal promoter. The vectors were transfected into SiHa cells, incubated for 24 h, treated for 4 h with hormones or TNF-    , and analyzed 
for luciferase activity. (B) Relative luciferase activity after estrogen treatment. Cells were transfected with constructs containing AID promoter fragments 
and treated with estrogen for 4 h. (C) Effect of TNF-     and estrogen on the human AID promoter. Expression construct with an AID promoter region con-
taining NF-    B sites and putative ERE (Fragment C) were transfected into cells, followed by TNF-     and/or estrogen treatment for 4 h. (D) Estrogen can act 
independently from NF-    B. Cells were cotransfected with Fragment C and an I   B   -mt expression vector. After 24 h, cells were treated with TNF-     and/or 
100 nM estrogen for 4 h. Timelines of cell treatments are indicated below the graphs. NT, not treated.     102 ESTROGEN INDUCES AID   | Pauklin et al. 
(or cotransfected with expression plasmids), and then ana-
lyzed for luciferase activity. As we were primarily interested 
in the eff  ect of hormones on expression, we used relative 
change as a readout rather than absolute values, which pro-
vided a more direct evaluation of the hormone treatment but 
potentially obscured the individual eff  ect of the various DNA 
elements. When compared with DMSO treatment, estrogen 
responsiveness was most signifi  cant with Fragment C, indi-
cating that this contained the predominant estrogen-respon-
sive DNA element. Comparable to the mRNA production 
of AID in B cells, Fragment C also responded in a dose-de-
pendent manner to estrogen (  Fig. 2 C  ). Aside from the puta-
tive ERE, Fragment C also harbored the two published 
NF-    B binding sites (  24  ). As indicated by the qRT-PCR 
analysis in   Fig. 1 A  , estrogen and the LPS/IL-4  –  induced NF-
    B stress-response pathway could act synergistically on AID 
mRNA production. To more directly stimulate the NF-    B 
pathway in SiHa cells, we used the cell-autonomous activa-
tor TNF-     (  Fig. 2 C  ). Interestingly, aside from the synergy 
the relative change did not signifi  cantly alter the overall ef-
fect, we did not pursue this analysis further, although recent 
data suggests that alternative splicing may infl  uence AID ex-
pression (  39  ). The experiments substantiate the notion that 
estrogen  ’  s main mode of action on AID is through transcrip-
tional regulation and not mRNA metabolism. 
  Identifi  cation of hormone response elements 
in the AID promoter regions 
  The rapid eff  ect of the hormones on AID message via tran-
scription suggested that the AID gene is a direct target for 
hormonal regulation. Using bioinformatic analysis (  Fig. 2 A  ), 
we were able to identify putative EREs in the context of 
other response elements, such as NF-    B.   We dissected the 
1.5 kb upstream and the 2 kb downstream of the ATG   regions 
for hormone-responsive elements in a heterologous transcrip-
tion assay. The potential response regions were placed into a 
luciferase reporter construct and transfected into human SiHa 
cells, followed by treatment with the indicated hormone 
    Figure 3.         Identifi  cation of ER binding to human AID promoter by EMSA and ChIP.   (A) Schematic representation of human AID promoter region 
(as in   Fig. 2 A  ). The position of the oligonucleotide used for EMSA and the region amplifi  ed by qRT-PCR for ChIP are marked as a black line and a dashed 
line, respectively. (B) Estrogen (denoted as E) -induced oligonucleotide shift (marked with an arrow) in Ramos nuclear extracts. Cells were treated for 72 h 
in hormone-depleted serum, followed by 4-h treatment with 10 nM estrogen (lanes 3 and 5  –  11) and/or TNF-     (lanes 4 and 5), and nuclear extract prepa-
ration. Different concentrations of unlabeled competitors ER (lanes 6  –  8) and mutated ER mut (lanes 9  –  11) were added to the binding reaction. Open tri-
angle, nonspecifi  c DNA binding band. (C) EMSA with anti-ER     antibodies. Increasing concentrations of anti-ER     antibody and a nonspecifi  c antibody 
were added to the binding reaction (see Materials and methods). The estrogen-induced band is marked with an arrow, and a super-shifted band appear-
ing upon anti-ER     antibody addition is marked with a closed triangle. Open triangle, nonspecifi  c DNA-binding band. (D) ER     binds to upstream region of 
human AID promoter. Cells were treated as in B. Data are representative of three independent experiments and error bars indicate standard deviations 
from the mean. ChIP was performed using anti-ER     or control antibodies, and the bound DNA was subjected to qRT-PCR. Estrogen and Tam treatments 
are marked with E1 (estrogen 1 nM), E10 (estrogen 10 nM), and Tam, respectively. (E) Estrogen can cooperate with TNF-     in recruiting NF-    B to AID pro-
moter. ChIP is as in D, using anti  –  NF-    B or control antibodies. NT, not treated.     JEM VOL. 206, January 19, 2009 
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dicated that the respective treatments did not alter the general 
DNA-binding properties of ER or NF-    B proteins. Because 
the distance, on the AID promoter, between the ER and 
NF-    B sites was larger than our EMSA probes (i.e., neither 
probe contained both binding sites), we could not study the 
eff  ect of cooperative binding. 
  ER binding to AID promoter in vivo 
  Although the in vitro binding of the ER to the AID pro-
moter indicated a direct binding, we also wanted to probe 
this interaction in vivo. To this end, we used the constitutive 
AID-expressing and mutating Burkitt lymphoma Ramos cells 
and performed chromatin immunoprecipitation (ChIP) assay, 
followed by qRT-PCR. Treated cells were fi  xed,  lysed, 
DNA sheared, and ER     or NF-    B immunoprecipitated, and 
the DNA was released for PCR. As shown in   Fig. 3 D  , the 
anti-ER antibody specifi  cally immunoprecipitated the AID 
promoter upon estrogen stimulation in a dose-dependent 
manner. A control antibody was unable to precipitate this re-
gion. Analogous to the EMSA assay, we did not detect a sig-
nifi  cant increase in ER binding to AID promoter when we 
co-stimulated with TNF-    , just as TNF-     treatment alone 
did not enhance ER binding. Again, cotreatment of cells 
with Tam and estrogen before ChIP did reduce the binding 
of ER     to the AID promoter, whereas Tam on its own did 
not signifi  cantly alter ER     binding (  Fig. 3 D  , E 10/Tam and 
Tam, respectively), providing further evidence for a direct 
binding of ER     to the AID promoter. Treatment of the cells 
with TNF-     increased the binding of NF-    B to the AID 
promoter by more than sevenfold (  Fig. 3 E  ). Interestingly, 
co-stimulation of the cells with TNF-     and estrogen had 
a synergistic eff  ect on the NF-    B binding; the binding in-
creased to   >  30-fold above unstimulated treatment (4.5-fold 
above TNF-     alone). 
  Estrogen up-regulates AID protein production 
  For us to determine if the eff  ect of estrogen on AID would 
also extend to the protein level, we developed a quantitative 
approach for measuring AID protein. We generated a DT40 
cell line (a cell line derived from a chicken B cell lymphoma 
that constitutively expresses AID and undergoes Ig diversifi  -
cation) to express a double tag (3xFLAG-2xTEV-3xc-Myc) 
fused to the C terminal exon of endogenous AID (AID FLAG-
Myc  –  tagged AID protein [AID-FM]; Fig. S4, available at 
http://www.jem.org/cgi/content/full/jem.20080521/DC1). 
The modifi  ed DT40 express a WT AID protein and an AID-
FM fusion protein, both transcribed from the endogenous 
AID locus. Comparing the qRT-PCR induction kinetics 
with that of the AID-FM expression, we determined that the 
steady-state levels of AID protein correlated to those of the 
mRNA (  Fig. 4, A and B  ).   Using the translation inhibitor 
CHX (  Fig. 4 C  ), we showed that estrogen was not able to 
increase AID-FM expression in the absence of translation. In 
the presence of the proteasome inhibitor MG-132 (  Fig. 4 C  ), 
estrogen increased AID-FM production above that of the 
MG-132 alone, indicating that estrogen was not acting on 
(e.g., 10      9   M), the two maxima of the dose response were 
off  set (TNF-     treated, 10      9   M; untreated, 10      7   M), indicat-
ing a higher complexity of the two interacting pathways. To 
demonstrate independence of the two pathways, we analyzed 
the response of Fragment C to treatment with TNF-     and 
estrogen upon cotransfection of the dominant-negative mu-
tant of I    B     (I    B     S32A/S36A dominant mutant [I    B    -
mt]), which is known to inhibit the release of NF-    B from 
the cytoplasm into the nucleus after stimulation. As shown in 
  Fig. 2 D  , the TNF-     activation was inhibited in the presence 
of I    B    -mt, yet estrogen was able to independently activate 
the transcription. This indicated that in the AID promoter, 
the NF-    B site and its proximal ERE could act indepen-
dently as well as synergistically. 
  ERE binding in B cell extracts 
  The transient transfection assay indicated that a predicted 
ERE was subject to estrogen regulation. Thus, we analyzed 
ER binding to the AID promoter and focused on the more 
widely expressed receptor subtype ER    . To analyze the bind-
ing of ER to parts of the AID promoter in vitro, we prepared 
nuclear extracts from treated and untreated cells and per-
formed electromobility shift assays (EMSA). For the bio-
chemical analysis of the ER binding to the ERE, we focused 
on NF-    B proximal ERE of Fragment C. A 34-bp fragment 
containing the 5    -most proposed ER binding site was incu-
bated with untreated and treated extract (  Fig. 3 B,   lanes 2 and 
3).   The estrogen treatment clearly induced a protein that 
could bind the fragment (arrow), which was not induced 
when treating the B cells with TNF-     before extract prepa-
ration (lane 4). Cotreatment with estrogen and TNF-     had 
the same eff  ect as estrogen alone (  Fig. 3 B,   lane 5), indicating 
that the two pathways act through diff  erent nuclear proteins. 
Competition experiments with the ER binding site (  Fig. 3 B,   
lanes 6  –  8) or a mutation of the proposed ER site (  Fig. 3 B,   
lanes 9  –  11) showed a specifi  c competition, indicating ER-
like binding kinetics. Using antibodies to the DNA-binding 
domain of ER     strongly inhibited the formation of the estro-
gen-induced band (  Fig. 3 C,   lanes 2 vs. 3  –  5), but the shift was 
unaff  ected by a control antibody (  Fig. 3 C,   lanes 2 vs. 6  –  8, 
arrow). The anti-ER     antibody did induce the appearance of 
a high molecular weight complex (  Fig. 3 C,   triangle in lanes 
4 and 5), which could be caused by either the supershift of a 
dimerized ER     or heterodimer ER    /ER    ; however, this 
needs to be analyzed further. 
  Because estrogen and TNF-     co-stimulation did not alter 
ER binding to the ERE, we wanted to determine if the re-
ciprocal of NF-    B binding to the NF-    B site, after the com-
bined treatment, was also unaff  ected. To that end, we probed 
the published NF-    B site (  24  ) with our extracts. Using cold 
competitors (Fig. S3 B, lane 4 vs. 6  –  11, available at http://www
.jem.org/cgi/content/full/jem.20080521/DC1), as well as 
anti  –  NF-    B antibodies (Fig. S3 C), we could demonstrate 
the specifi  city of the NF-    B binding site. As with the ER 
binding site, NF-    B binding was not altered by cotreatment 
with estrogen and TNF-     (Fig. S3 B, lanes 4 vs. 5). This in-104 ESTROGEN INDUCES AID   | Pauklin et al. 
produces switch circle transcripts; it is generated from the 
promoter of the downstream switch region and the Ig     switch 
region. Using a previously described qRT-PCR approach (  40  ), 
we were able to show enhanced switching to IgG1, IgG3, 
IgA, or IgE after hormone treatment of splenic B cells (  Fig. 
5 A  ).   Presumably through the increased production of AID, 
estrogen was able to enhance switch circle formation for all 
subclasses tested. As with the AID production, this link was 
perturbed with the addition of Tam during estrogen treat-
ment (  Fig. 5 A  , Estrogen 10 nM/Tam and Tam). 
  To determine the eff  ect of estrogen-induced AID on 
SHM, we sequenced the VH region of in vitro  –  cultured 
Ramos cells, as well as the switch region of     3 from ex vivo  –
  stimulated splenic B cells. A 3-wk estrogen treatment of 
Ramos HS13 (  41  ), which possesses a premature stop codon 
embedded within the AID target motif WRC, showed en-
hanced surface Ig expression and VH SHM (  Fig. 5 B   and 
Fig. S6, available at http://www.jem.org/cgi/content/full/
jem.20080521/DC1). Because Ramos expresses constitutive 
amounts of AID, estrogen treatment did not enhance AID 
the proteasome to increase AID-FM activity. The aforemen-
tioned co-stimulatory eff  ects of TNF-     were also observed at 
the level of protein production (  Fig. 4  , E 10/TNF-    ). 
  Hormonal regulation of CSR and SHM 
  On the molecular level, CSR requires AID, yet regulation 
can be achieved on multiple levels, some of which may be 
hormonally infl   uenced. To analyze CSR, isolated mouse 
splenic B cells were treated with diff  erent combinations of 
cytokines and hormones. B cell stimulation with LPS, LPS 
and IL-4, LPS and IFN-    , or LPS and TGF-     results in 
switching to IgG3, IgG1, IgG2a, or IgG2b/IgA, respectively. 
To ensure we could correlate AID activity precisely, and to 
avoid possible proliferative and antiapoptotic eff  ects of estro-
gen on stimulated B cells, we monitored the early molecular 
events of class switching. One of the molecular intermediates 
during class switching is the generation of a looped-out circu-
lar DNA called a switch circle (Fig. S5, available at http://
www.jem.org/cgi/content/full/jem.20080521/DC1). The 
circular DNA contains a recombined transcription unit that 
    Figure 4.         The effects of estrogen on AID protein in DT40.   (A) Estrogen induces AID mRNA expression. AID-FM  –  tagged DT40 cells were treated with 
DMSO, 100 nM estrogen, and 10 nM estrogen with TNF-    , lysed, and analyzed for AID mRNA expression with pRT-PCR at various time-points. (B) Estro-
gen induces AID-FM fusion protein expression. Treatment as in A, but lysates were analyzed by quantitative Western blot. For each sample, FLAG and 
Tubulin expression was quantitated. The graph is derived from correlating the FLAG expression to Tubulin expression, and then determining the ratio of 
estrogen-induced FLAG expression to untreated DMSO samples. (C) Estrogen does not affect AID-FM fusion protein stability. Cells were incubated with 
CHX or MG-132 for 2 h, followed by estrogen treatment for 4 h. Protein levels were determined by quantitative Western blot. For all experiments, cells 
were grown in hormone depleted media for 48 h. Results are normalized to control treatments as indicated on each graph. Timelines of cell treatments 
are indicated below the graphs.     JEM VOL. 206, January 19, 2009 
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production substantially; thus, we used the ex vivo treatment 
of spleens as a means to detect mutations in the switch region 
(  42  ). To this end, we treated LPS-activated splenic B cells 
with 10 nM estrogen for 6 d and sequenced the S    3 region. 
Because AID  +/      mice show a haploinsuffi   ciency eff  ect (  43, 44  ), 
we used F1 spleens from an AID      /      and BALB/c cross for 
analysis, hypothesizing that the estrogen eff  ect would be more 
pronounced. As can be seen in   Fig. 5 B   and Fig. S7, there was 
a signifi  cant (P   <   0.02) enhancement of mutation frequency 
in the switch region after estrogen treatment. 
  Enhanced non-Ig loci targeting of AID 
  It is known that AID can be mistargeted to non-Ig genes 
(  12, 17  –  19  ). The eff  ect of aberrant AID targeting can lead to 
somatic mutations or even translocations of protooncogenes 
or tumor suppressors, and subsequently to oncogenesis (  16  ). 
To determine if the activity of hormones via AID can also 
lead to an alteration in non-Ig loci, we chose to look at the 
proapoptotic tumor suppressor CD95/Fas. CD95/Fas has been 
shown to be somatically hypermutated in human B cells, al-
beit 100  –  1,000-fold less frequently than the Ig genes (  18  ). 
We analyzed the eff  ects of estrogen on CD95/Fas mutations 
in Ramos HS13. As with the physiological B cell maturation 
events of SHM and CSR, estrogen was able to increase the 
potentially pathogenic mutation frequency in CD95/Fas 
(  Fig. 5 C   and Fig. S7 B). Because of the direct eff  ect on AID 
function (mutation), this data provides evidence for a novel 
way in which estrogen can exert a direct genotoxic eff  ect on 
oncogenes or tumor suppressors. 
  Estrogen enhances c-myc IgH translocations 
  The off  -target eff  ect of AID was also detected in recent work 
on chromosome translocations of the c-myc oncogene into 
the IgH locus. More importantly, the levels of AID protein 
directly infl  uenced chromosome translocation frequency. 
This was determined from both the analysis of AID haploin-
suffi   ciency (  44  ) and microRNA regulation of AID protein 
expression (  45, 46  ). In both cases, reduced levels of AID had 
a direct bearing on the number of observed c-myc/IgH 
translocations. Using a previously described assay (  16, 47  ), we 
were able to determine that estrogen treatment of isolated 
    Figure 5.         Hormonal effects on Ig class switching, hypermuta-
tion, and translocation.   (A) Estrogen induces isotype switching. 
Isolated mouse splenic B cells were stimulated for 48 h with LPS + IL-4 
for switching to IgG1 and IgE, LPS + TGF-     for switching to IgA, and 
LPS for switching to IgG3. Indicated amounts of estrogen and/or Tam 
were added to the cells together with cytokines. Relative effi  ciency of 
class switching was determined by detecting circle transcripts with 
qRT-PCR, and data are normalized to the control treatment with DMSO 
from three independent experiments (error bars indicate standard 
deviations). (B) Estrogen increases the mutation frequency in VH and 
CD95/Fas loci of Ramos, and in S    3 of splenic mouse cells. Ramos cells 
were grown in the presence of 100 nM estrogen for    20  doublings, 
followed by sequencing of 341 bp from human VH or 750 bp from hu-
man CD95/Fas locus. Splenic mouse cells were treated for 6 d with LPS 
and 10 nM estrogen, and switch gamma3 loci amplifi  ed and sequenced 
(Fig. S7). Mutation frequencies are normalized to the control treatments 
with DMSO. A standard unpaired two-tailed Student  ’  s   t   test showed a 
signifi  cant difference in mutation frequency in the S    3 loci of DMSO- 
and estrogen-treated spleen cells. (C) Estrogen enhances the c-myc/IgH 
translocations in splenic B cells from p53  +/      mice. In each experiment, 
2 spleens per sample were treated with or without 50 nM estrogen in 
the presence of LPS for 72 h. More than 7   ×   10  7   cells were analyzed by 
long-range PCR (5   ×   10  4   cells/PCR; Fig. S8 and Supplemental materials 
and methods). Frequency was determined as c-myc/IgH translocation 
events per cell number analyzed. Statistics was performed on the results 
of the pooled experiments (two-tailed, unpaired Student  ’  s   t   test: P = 0.026). 
Fig. S7, Fig. S8, and Supplemental materials and methods are available 
at http://www.jem.org/cgi/content/full/jem.20080521/DC1.     
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apparent catalytic activity (  34  ), was not aff  ected by estrogen 
treatment; however, we were able to show that estrogen enhan-
ced transcription of mouse Apobec3 from ovaries, spleen, and 
splenic B cells (  Fig. 6  ). Expression of human APOBEC3B, 
3F, and 3G family members was also enhanced upon estrogen 
treatment from several diff  erent cell lines (including those of 
T cell, ovarian, placental, and cervical origin; Fig. S9). 
    DISCUSSION   
  The physiological panpleiotropic eff   ects of hormones are 
well documented in many aspects of development, although 
their eff  ector mechanisms at the molecular level, as well as their 
pathogenic eff  ects upon cancer and immunity are not well 
understood (i.e., the gender bias for autoimmunity [  29, 31, 50  ] 
splenic B cells enhances c-myc/IgH translocations in p53  +/      
animals (  Fig. 5 C   and Fig. S8, available at http://www.jem
.org/cgi/content/full/jem.20080521/DC1). Although, the 
overall frequency of translocations was low, we have not 
been able to observe any translocations in LPS/DMSO-
treated spleen cells, yet we observed fi  ve (two in one experi-
ment and three in another) translocations in the LPS/estrogen 
treatment. This highlights the importance of regulating AID 
protein amounts within a cell, and the potential pathogenic 
consequences of unregulated AID expression. 
  AID induction is not limited to B cells 
  In the past, we demonstrated that AID mRNA expression is 
not limited to activated B cells, but can also be detected in 
oocytes (  22  ). We therefore set out to determine if the increase 
in AID mRNA production by estrogen was also detectable 
in dissected tissues and various tumor cell lines. Analysis of 
dissected organs and tissue from mice showed AID respon-
siveness to hormones outside the immune system in breast 
and ovarian tissue (  Fig. 6  ).   As we were primarily interested in 
the hormone sensitivity of the transcripts, we determined the 
relative fold stimulation compared with DMSO, which did 
not refl  ect the absolute AID mRNA in each tissue. Interest-
ingly, in ovaries, AID mRNA was induced almost 25-fold, 
which is higher than in any other organ or tissue. Because 
isolated oocytes produce AID mRNA (  22  ), we suggest that 
the increase was predominantly caused by oocytes or other 
ovarian-derived tissue, rather than infi  ltrating lymphocytes. 
  Gross tissue dissection can provide a good indication of 
possible cell types that can induce AID mRNA upon estrogen 
treatment, but tissue complexity could also obscure potential 
targets. Although we did not detect a substantial mRNA in-
crease in hepatocyte or cervix cell lines (Fig. S9, available at 
http://www.jem.org/cgi/content/full/jem.20080521/DC1), 
we were able to show a signifi  cant increase (ranging from 
2.5- to 22-fold) of AID in cell lines, including T cells, pla-
centa, ovary, breast, and prostate. The induction observed 
in breast cells mimics that of the tissues isolated in   Fig. 6 A  , 
and confi  rms a previous report that AID has been detected 
in the breast cell line MCF-7 (  48  ). Importantly, AID mRNA 
was not only present at basal levels but was also signifi  cantly 
up-regulated. 
  Estrogen activates APOBEC3B, 3F, and 3G 
mRNA transcription 
  AID is the ancestral member of the DNA deaminase family, 
and the APOBEC3 members are considered to have arisen 
from AID by gene duplication events (  34  ). Within the DNA 
deaminase family, APOBEC3 members function predomi-
nantly in the cytoplasm and inactivate foreign DNA such 
as retroviruses and retrotransposable elements (  49  ). We hypo-
thesized that hormonal responsiveness may have been con-
served among members of the APOBEC3 family. To this 
end, we designed qRT-PCR primers to detect APOBEC 
family member mRNAs in mouse and human cells. APO-
BEC2, a related member of the DNA deaminases without any 
    Figure 6.         Estrogen induces AID and Apobec3 transcription in 
mouse tissue.   The red and blue colors indicate the results for mApobec3 
and mAID, respectively. Tissues were treated with DMSO, 1 nM estrogen 
(E1), or 10 nM estrogen (E10). Gene expression is normalized to the con-
trol treatments with DMSO. The tissue expression profi  les represent 
pooled data for the respective tissues from two experiments. Timelines of 
cell treatments are indicated below the graphs. Absolute values as com-
pared with GAPDH mRNA are shown in Fig. S10, available at http://www
.jem.org/cgi/content/full/jem.20080521/DC1.   JEM VOL. 206, January 19, 2009 
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eff  ects. There are several hypotheses on how unregulated AID 
can aff  ect autoimmunity in addition to overstimulation of 
SHM and CSR, e.g., debilitating mutations in the signaling 
pathways, of tumor suppressors, or of proapoptotic genes, or 
alterations that activate oncogenes or antiapoptotic genes (for 
review see reference [  55  ]). 
  Mutation and subsequent loss of growth control is usually 
associated with oncogenesis, and this similarity with autoim-
munity has previously been noted (  55  ) (e.g., mutations in 
CD95/Fas have been associated with autoimmunity, as well 
as B cell lymphomas). Therefore, our data on estrogen-in-
duced mutations in CD95/Fas (  Fig. 5   and Fig. S7), derived 
from increased AID production, may provide a novel molec-
ular mechanism that is important for both pathologies. AID  ’  s 
targeting outside the Ig locus, its apparently crucial involve-
ment with germinal center  –  derived B cell malignancies 
(  43, 56  ), and its ability to cause various malignancies when 
overexpressed in transgenic mice (  20, 21, 57  ) are strong indi-
cators for AID  ’  s oncogenic potential. 
  Estrogen is one of the most important and thoroughly 
studied mitogenic agents in cancer, but it does not possess 
any direct DNA mutability, and induces transformation by 
proliferation. In vitro, high concentrations of estrogen deriv-
atives (usually metabolites) can form DNA adducts or produce 
reactive oxygen-damaging DNA (for review see reference 
[  58  –  60  ]), but their role as physiological genotoxins is limited. 
Furthermore, because the estrogen derivative Tam (  61  ) can 
inhibit estrogen  ’  s oncogenesis in breast cancer, it is unlikely 
that estrogen (or its derivatives) form DNA adducts under 
those conditions. It is interesting to note that the antagonistic 
activity of Tam has recently been used to inhibit some of the 
pathologies of estrogen-induced autoimmunity (  54  ). On the 
other hand, because of the pharmacological action of Tam 
(binding and altering the ER DNA binding capacity), under 
certain circumstances Tam acts as an estrogen agonist (  62  ). 
This activity leads to an increased risk in secondary (e.g., 
ovarian) cancer after Tam treatment for breast cancer (  63  ). 
Thus, our fi  ndings that low concentrations of Tam induced 
AID mRNA (Fig. S1) also suggest that Tam acts as an agonist 
and indicates that the proposed usage of synthetic estrogen 
derivatives as a means to inhibit AID has to be carefully eval-
uated. Future work on identifying a potential role of AID in 
mouse models of hormonally induced cancers may provide 
further evidence on how AID can act as an environmentally 
stimulated oncogene. 
  As our data indicate, AID  ’  s response to estrogen seems to 
have been evolutionarily conserved among the APOBEC3 
family members, diff  erent tissues, and cell lines (  Fig. 6   and 
Fig. S8); mouse Apobec3 and human APOBEC3B, -3F, and 
-3G (and -H to a lesser extent) mRNA were induced by es-
trogen treatment. In the past, we have hypothesized that the 
predominant function of AID and its evolved DNA deami-
nase family members was to inactivate foreign DNA in the 
cell (  8, 34, 64, 65  ). It is therefore plausible that the observed 
estrogen response of AID, as well as its expression in oocytes 
(  22  ), had served a purpose other than targeting AID to Ig 
is as striking as the gender bias for some cancers [  51, 52  ]). 
The correlation between the expression of hormones or their 
cognitive receptors and development of pathologies, has led 
to several diff  erent hypotheses; most of which involve hyper-
activation of cell proliferation, unregulated diff  erentiation, 
alteration in DNA repair, or repression of apoptosis (  51  ). 
Here, we propose another means by which estrogen can be 
a genotoxin, by directly inducing DNA deaminases such as 
AID. Our initial experiment using progesterone and estrogen 
identifi  ed AID as being part of a hormonally regulated sys-
tem. Estrogen exerted its activity through the estrogen  –  ER 
complex, directly binding to the AID promoter, whereas our 
preliminary data suggests that progesterone acts through an 
estrogen-independent pathway (unpublished data). The con-
sequences of estrogen activation on AID mRNA could also 
be detected as an increase in AID protein and enhanced 
downstream physiological eff  ects, such as SHM and CSR. 
Interestingly, AID activation (mRNA) by estrogen was more 
pronounced than the eff  ect on SHM. This could indicate that 
although AID production is necessary for SHM, other factors 
(e.g., lesion processing, AID targeting, etc) can play a signifi  -
cant role in overall SHM effi   ciency (  53  ). Similar to SHM, 
CSR was enhanced upon estrogen treatment, but was lag-
ging behind AID mRNA production. The most dramatic ef-
fect from estrogen-induced overexpression of AID was seen 
at the level of c-myc/IgH translocations. This is analogous 
to the recent observations that the eff  ect of AID mRNA 
down-regulation (either by microRNA targeting or haploin-
suffi   ciency) was most pronounced at the level of transloca-
tions (  44  –  46  ). 
  Autoimmunity encompasses a broadly defi  ned area of 
clinical pathologies that stem from abnormalities in numer-
ous systemic, cellular, and molecular mechanisms, a subset 
of which are B cell  –  related pathologies (  50  ). In systemic lu-
pus erythematosus, abnormalities in B cell development and 
the production of autoreactive antibodies play an important 
pathological role. Overexpression of AID in autoimmune-
prone mice induced a more severe systemic lupus erythema-
tosus  –  like phenotype (  10  ), whereas breeding AID-defi  cient 
mice with autoimmune-prone MRL/lpr mice signifi  cantly 
reduced the onset and extent of disease (  11  ), indicating that 
alterations in AID can change the severity of B cell auto-
immunity. Correlating our data with the known eff  ects of 
estrogen on autoimmunity (  28, 30, 50, 54  ), we propose that 
the eff  ect of sex-hormones on autoimmunity could partially 
be through AID transcription and subsequent increase in ge-
nome instability. In addition to the direct binding of the es-
trogen  –  ER complex to the AID promoter, estrogen may also 
hyperstimulate AID production through the NF-   B pathway, 
as we were able to demonstrate that cotreatment of TNF-     
and estrogen enhanced NF-    B binding to the AID promoter 
(  Fig. 3 D  ). Whether this eff  ect is caused by protein  –  protein 
interaction or estrogen-induced chromatin modifi  cation has 
yet to be determined, but the synergistic or even cooperative 
interaction of two important autoimmune modulator path-
ways on AID expression may have substantially pathogenic 108 ESTROGEN INDUCES AID   | Pauklin et al. 
were treated with the indicated concentrations of hormones or TNF-     for 4 h 
and analyzed thereafter for luciferase signal using Dual Luciferase Reporter 
Assay System (Promega) and Glomax luminometer (Promega). The expression 
vector containing a dominant-negative mutant for I    B     (S32A S36A; a gift 
from Felix Randow, Medical Research Council-Laboratory of Molecular 
  Biology, Cambridge, England, UK) was cotransfected with pE1BLuc constructs 
where indicated. 1     g CMV promoter-driven Renilla luciferase expression 
vector (Promega) was included in all transfections and used as an internal con-
trol for transfection effi   ciency. 
  EMSA.     Ramos cells were treated for 72 h in hormone-depleted serum before 
the 4-h hormone treatment. EMSA was performed by standard protocol (  68  ) 
with minor modifi  cations (for more detail see Supplemental materials and 
methods). 0.25 pmol of complementary oligonucleotides containing either 
NF-    B or putative ER binding elements were annealed, labeled, and added to 
7   μ  g of Ramos (treated or untreated) nuclear extract. Reactions were incu-
bated for 20 min at room temperature in the absence or presence of 1-, 3-, and 
10-fold mass excess of unlabeled oligonucleotides or antibodies. Samples were 
electrophoresed at 4  °  C on 4.5% polyacrylamide gels for 120 min, followed by 
autoradiography on imaging plates (FujiFilm) and analysis with a FLA-5000 
Scanner (FujiFilm). 
  ChIP.     Ramos cells were treated for 72 h in hormone-depleted serum before 
the 4-h hormone treatment. ChIP procedure was done as previously pub-
lished, with minor modifi  cations (  69  ) (for further details see Supplemental ma-
terials and methods). Approximately 10  7   cells were fi  xed with 1% formaldehyde 
in the culture media for 10 min at 37  °  C, and then quenched with 0.125 M 
glycine for 5 min at RT. Cells were pelleted and washed twice with cold PBS. 
The cell pellet was resuspended in 300   μ  l SDS lysis buff  er and incubated on ice 
for 10 min. Cell lysates were sonicated for 6 min with a 30-s on/off   sonication 
cycle in 1.5 ml eppendorf tubes. Samples were centrifuged for 5 min at 13,000 
rpm at 4  °  C, and supernatants were diluted to 1.5 ml with ChIP buff  er. An ali-
quot was kept as input measurement. Samples were precleared with 60   μ  l Pro-
tein G beads (ProtG; Roche) and 1   μ  g salmon sperm DNA (Invitrogen) for 
45 min at 4  °  C. Anti  –  NF-    B p65 antibody, rabbit anti-ER     HC-20 antibody 
(Santa Cruz Biotechnology, Inc.), or goat anti  –  mouse   	   control antibody (see 
Supplemental materials and methods) was added to the supernatant at a con-
centration of 2   μ  g/assay and incubated for 12 h at 4  °  C. 60     l of salmon sperm 
DNA (1   μ  g DNA/20   μ  l ProtG) was added to the samples and incubated for 
1 h while rotating. The ProtG  –  antibody  –  protein complex was pelleted and 
washed with the following buff  ers: low-salt wash buff  er, high-salt wash buff  er, 
LiCl wash buff  er, and standard TE buff  er (twice). The sample was eluted with 
250   μ  l of elution buff  er and incubated for 15 min at room temperature with 
agitation. The beads were centrifuged and the elution was repeated once. 
Bound immunocomplexes were then reverse cross-linked with 200 mM NaCl 
by incubating it at 65  °  C for 12 h. Proteinase K was added to the sample and 
incubated for 1 h at 45  °  C. DNA was then extracted with phenol/chloroform 
and precipitated, resuspended in 50   μ  l of water and subjected to qRT-PCR, 
using CHIP1 and CHIP2 primers for amplifying the     1,189 to     1,039 re-
gion of the AID promoter. 
  sIgM fl  uctuation analysis.     The surface IgM (sIgM) expression was inves-
tigated in Ramos HS13 cells (  41  ), which contain a stop codon in the   	   locus, 
with reversion mutations resulting in sIgM production. IgM stained (anti  –
  human IgM-FITC [Sigma, UK]) and sorted single sIgM-negative cells were 
grown for     20 doublings, with fresh hormone containing media added ev-
ery 48 h. The cells were then stained (anti  –  human IgM-FITC) for surface 
expression of IgM and analyzed by fl  ow cytometry. 
  Mutation analysis.     VH and C regions were cloned and sequenced from 
hormonally treated (20 doublings) Ramos HS13 cells, as previously de-
scribed (  41  ). The human CD95/Fas locus was PCR amplifi  ed and sequenced 
from isolated genomic DNA, as previously described (  18  ). Mouse S    3 
switch regions were analyzed from 2 AID  +/      spleens and treated with either 
genes in B cells. Data indicating that AID has retained some 
ability to inhibit retroviral elements have substantiated this 
hypothesis (  66  ). 
  Our work has highlighted that there is a novel pathway 
by which the nonmutagenic hormone estrogen can medi-
ate genome instability via the activation of AID and other 
DNA deaminases, in turn possibly altering the predisposi-
tions, induction, or severity for cancer, autoimmunity, and 
viral infectivity. 
    MATERIALS AND METHODS   
  Cells and tissue.     Unless indicated, mouse tissue samples and splenic B cells 
were derived from 8  –  12-wk-old female unplugged BALB/c mice, and pre-
pared by standard protocol (see Supplemental materials and methods, available 
at available at http://www.jem.org/cgi/content/full/jem.20080521/DC1). 
Human cell lines Jurkat, T47D, Ramos HS13 (Ramos), JAR, and mouse 
B cells were cultivated in RPMI-1640+GlutaMax medium (Invitrogen); the 
cell lines MCF7, JAMA2, HeLa, and HepG2 were cultivated in E4 medium; 
and PC3 was cultivated in HAMS F12 medium. Chicken DT40 cells were 
maintained in RPMI-1640+GlutaMax with 10% FCS, 1% chicken serum, 
50   μ  M     -mercaptoethanol, 100 U/ml penicillin, and 100   μ  g/ml streptomy-
cin at 39  °  C with 10% CO  2  . For indicated experiments, cells were treated 
for 72 h in hormone-depleted serum (Opti-MeM Reduced Serum Medium; 
Invitrogen) supplemented with Charcoal Stripped Fetal Bovine Serum (In-
vitrogen); and nonessential amino acids (fi  nal concentration; Sigma-Aldrich), 
as follows:   l-  Alanine (8.9   μ  g/ml),   l-  Asparagine (15.0   μ  g/ml),   l-  Aspartic acid 
(13.3   μ  g/ml),   l-  Glutamic acid (14.7   μ  g/ml), Glycine (7.5   μ  g/ml), Proline 
(11.5   μ  g/ml), and   l-  Serine (10.5   μ  g/ml). 
  Reagents.     B cell stimulation was performed using 25   μ  g/ml LPS (Sigma-
Aldrich), 50 ng/ml mouse IL-4 (R  &  D Systems), 20 ng/ml human TNF-     
(R  &  D Systems), and 2 ng/ml human TGF-    1 (R  &  D Systems). Estrogen 
(17-    -estradiol; Sigma-Aldrich) and progesterone (Sigma-Aldrich) were dis-
solved in DMSO at a concentration of 100 mM; this solution was then di-
luted in DMSO to give 1,000  ×   stock solutions, and fi  nal dilutions were 
made in media (fi  nal DMSO concentration was never   >  0.1%). The fi  nal 
concentrations of estrogen are indicated in the text and fi  gure legends. The 
concentration of Tam (Sigma-Aldrich) was 50 nM unless otherwise stated. 
The fi  nal concentration for CHX (Sigma-Aldrich) was 10   μ  g/ml, 20 nM 
for ACT (Calbiochem), 4   μ  g/ml for AMA (Calbiochem), and 10   μ  M for 
MG-132 (Sigma-Aldrich). 
  RT-PCR and qRT-PCR.     qRT-PCR of mRNAs was based on a previous 
study (  67  ), with modifi  cations (see Supplemental materials and methods). 
The primers for qRT-PCR (Table S1, available at http://www.jem.org/
cgi/content/full/jem.20080521/DC1) were designed using PrimerExpress 
software. qRT-PCR analysis was performed using the QuantiTect SYBR 
Green PCR kit (QIAGEN) according to the manufacturer  ’  s instructions, 
Abi 7000 Sequence Detection System (Applied Biosystems), and Abi 
software. Tissue or cell line hormone responsiveness was determined by 
qRT-PCR of gene regulated by breast cancer 1, a known estrogen-responsive 
gene (  36  ). 
  Promoter analysis.     Human AID promoter fragments were analyzed using 
pE1BLuc plasmid backbone (provided by G. Akusj  ä  rvi, Uppsala University, 
Uppsala, Sweden) containing a luciferase ORF and a minimal promoter 
region. Primers (Tables S2 and S3, available at http://www.jem.org/cgi/ 
content/full/jem.20080521/DC1) approximately every 500 bp from the hu-
man AID transcription start site were used for amplifying AID promoter 
regions. The obtained PCR products were cloned into pE1BLuc vector, and 
3   μ  g DNA were transfected into SiHa cells using Lipofectamine 2000 (Invit-
rogen) according to the manufacturer  ’  s protocols. 24 h after transfection, cells JEM VOL. 206, January 19, 2009 
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